Methods for diagnosis and treatment of tumours

Use of a peptide comprising

• aa) an antigen-binding site for the extra domain B (ED-B) of fibronectin comprising complementarity-determining regions HCDR3 and/or LCDR3 as shown in Table 1 or a variation thereof that is a deletion, insertion and/or substitution of up to 5 amino acids for the HCDR3 region and up to 6 amino acids for the LCDR3 region which has the same function as a peptide according to Seq. Id. No. 1;
• ab) an antigen-binding site for the extra domain B(ED-B) of fibronectin comprising complementarity-determining regions HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 as shown in Table 1 or a variation thereof that is a deletion, insertion and/or substitution of up to 3 amino acids for the HCR1 region, up to amino acids for the HCDR2 region, up to 5 amino acids for the HCDR3 region, up to 6 amino acids for the LCDR1 region, up to 4 amino acids for the LCDR2 region and up to 6 amino acids for the LCDR3 region;
• which has the same function as a peptide according to Seq. Id. No. 1;
• or
• ac) a sequence according to Seq. Id. No. 1 (L19) or a variation of Seq. Id. No. 1 that is a deletion, insertion and/or substitution of up to 30 amino acids an which has the same function as a peptide according to Seq. Id. No. 1,
• and
• ba) an amino acid sequence Xaa1-Xaa2-Xaa3-Cys (Seq. Id. No.2), wherein Xaa1, Xaa2 and Xaa3 each independently represent any naturally occuring amino acid or
• bb) an amino acid sequence Xaa1-Xaa2-Xaa3-Cys-Xaa4(Seq. Id. No. 3), wherein Xaa1, Xaa2, Xaa3, and Xaa4 each independently represent any naturally occuring amino acid or
• bc) an amino acid sequence (His)n (Seq. Id. No. 4), wherein n stands for an integer from 4 to 6,
• wherein the C-terminus of aa), ab) or ac) is bound to the N-terminus of one of the sequences Seq. Id. No. 2, Seq. Id. No. 3 or Seq. Id. No. 4 via a peptide bond,
• for binding a radioisotope.